{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:45:04Z","timestamp":1788209104671,"version":"build-2803163510"},"reference-count":73,"publisher":"Georg Thieme Verlag KG","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary aldosteronism (PA) is detected with increasing frequency in hypertensive\n                    patients and is associated with excess cardiovascular, renal, and metabolic\n                    complications. For these reasons, appropriate choices for treatment of this\n                    endocrine condition are mandatory. Adrenalectomy is safely performed in PA\n                    patients when adrenal venous sampling (AVS) demonstrates lateralized aldosterone\n                    secretion. AVS, however, is a complex procedure and even among worldwide\n                    referral centers there are substantial discrepancies for interpretation of\n                    results. Also, in the majority of PA patients with lateralized aldosterone\n                    secretion, hypertension may persist after adrenalectomy requiring use of\n                    additional antihypertensive agents. Treatment with mineralocorticoid receptor\n                    antagonists (MRAs) is currently recommended for PA patients with bilateral\n                    adrenal disease, but these agents effectively decrease blood pressure also in\n                    patients with unilateral disease, although concern remains for possible\n                    sex-related side effects. Prospective studies indicate that MRAs have\n                    therapeutic values comparable to surgery in the long-term, inasmuch as they\n                    effectively correct metabolic abnormalities and subclinical organ damage and\n                    reduce the risk of cardiovascular events and renal disease progression. This\n                    article overviews the clinical outcomes obtained in patients with PA with use of\n                    MRAs.<\/jats:p>","DOI":"10.1055\/s-0035-1565128","type":"journal-article","created":{"date-parts":[[2015,12,15]],"date-time":"2015-12-15T00:17:57Z","timestamp":1450138677000},"page":"1000-1006","source":"Crossref","is-referenced-by-count":20,"title":["Mineralocorticoid Receptor Antagonists and Clinical Outcomes in\n                    Primary Aldosteronism: As Good as Surgery?"],"prefix":"10.1055","volume":"47","author":[{"given":"G. L.","family":"Colussi","sequence":"first","affiliation":[{"name":"Internal Medicine, Department of Experimental and Clinical Medical\n                    Sciences, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Novello","sequence":"first","affiliation":[{"name":"Internal Medicine, Department of Experimental and Clinical Medical\n                    Sciences, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Uzzau","sequence":"first","affiliation":[{"name":"General Surgery, Department of Experimental and Clinical Medical\n                    Sciences, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Catena","sequence":"first","affiliation":[{"name":"Internal Medicine, Department of Experimental and Clinical Medical\n                    Sciences, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. A.","family":"Sechi","sequence":"additional","affiliation":[{"name":"Internal Medicine, Department of Experimental and Clinical Medical\n                    Sciences, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2015,12,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ajh.2010.169","article-title":"Cardiovascular and renal damage in primary aldosteronism: outcomes after\n                    treatment","volume":"23","author":"L A Sechi","year":"2010","journal-title":"Am J Hypertens"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/jc.2014-3663","article-title":"Update in primary aldosteronism","volume":"100","author":"M Stowasser","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism:\n                    an endocrine society clinical practice guideline","volume":"93","author":"J W Funder","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.ackd.2014.10.003","article-title":"Outcomes of drug-based and surgical treatments for primary aldosteronism","volume":"22","author":"O Steichen","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/bjs.9744","article-title":"Systematic review of surgery and outcomes in patients with primary\n                    aldosteronism","volume":"102","author":"A Muth","year":"2015","journal-title":"Br J Surg"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/EJE-14-0585","article-title":"Mineralocorticoid antagonist treatment for aldosterone-producing adenoma","volume":"172","author":"L Amar","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1021\/jo01088a004","article-title":"Steroidal aldosterone blockers","volume":"24","author":"J Cella","year":"1959","journal-title":"J Org Chem"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","article-title":"Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and\n                    their effects on potassium homeostasis","volume":"10","author":"D A Sica","year":"2005","journal-title":"Heart Failure Reviews"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","article-title":"Spironolactone, eplerenone and the new aldosterone blockers in endocrine and\n                    primary hypertension","volume":"31","author":"G L Colussi","year":"2013","journal-title":"J Hypertens"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJM197412052912309","article-title":"Prolonged alteration of renin responsiveness after spironolactone therapy. A\n                    cause of false-negative testing for low-renin hypertension","volume":"291","author":"S C Lowder","year":"1974","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate\n                    hypertension","volume":"15","author":"M H Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of\n                    eplerenone and spironolactone in patients with hypertension and evidence of\n                    primary aldosteronism","volume":"29","author":"H K Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1161\/CIRCULATIONAHA.107.690396","article-title":"The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind\n                    crossover trial in patients with low-renin hypertension and elevated\n                    aldosterone-renin ratio","volume":"116","author":"S J Hood","year":"2007","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1210\/jc.2012-1917","article-title":"A clinical prediction score to diagnose unilateral primary aldosteronism","volume":"97","author":"E M Kupers","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11154-011-9156-6","article-title":"Diagnosis and treatment of primary aldosteronism","volume":"12","author":"P Mulatero","year":"2011","journal-title":"Rev Endocr Metab Disord"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.113.02097","article-title":"An expert consensus statement on use of adrenal vein sampling for the subtyping\n                    of primary aldosteronism","volume":"63","author":"G P Rossi","year":"2014","journal-title":"Hypertension"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S2213-8587(14)70069-5","article-title":"Adrenal vein sampling in primary aldosteronism: towards a standardised\n                    protocol","volume":"3","author":"S Monticone","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/HYPERTENSIONAHA.110.168484","article-title":"Adrenal venous sampling. Evaluation of the German Conn\u2019s registry","volume":"57","author":"O Vonend","year":"2011","journal-title":"Hypertension"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1161\/HYPERTENSIONAHA.109.146613","article-title":"Impact of different diagnostic criteria during adrenal vein sampling on\n                    reproducibility of subtype diagnosis in patietns with primary aldosteronism","volume":"55","author":"P Mulatero","year":"2010","journal-title":"Hypertension"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/HYPERTENSIONAHA.114.04812","article-title":"Influence of diagnostic criteria in the interpretation of adrenal vein\n                    sampling","volume":"65","author":"G Lethielleux","year":"2015","journal-title":"Hypertension"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00423-010-0681-7","article-title":"11C-methomidate positron emission tomography after dexamethasone suppression for\n                    detection of small adrenocortical adenomas in primary aldosteronism","volume":"395","author":"J Hennings","year":"2010","journal-title":"Langenbecks Arch Surg"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s002689900552","article-title":"Success for surgery for primary aldosteronism judged by residual autonomous\n                    aldosterone production","volume":"22","author":"J C Rutherford","year":"1998","journal-title":"World J Surg"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1677\/ERC-08-0094","article-title":"Medical treatment as an alternative to adrenalectomy in patients with\n                    aldosterone-producing adenomas","volume":"15","author":"A Karagiannis","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/HJH.0b013e328350225d","article-title":"Blood pressure and medication changes following adrenalectomy for unilateral\n                    primary aldosteronsim: a follow-up study","volume":"30","author":"P van der Linden","year":"2012","journal-title":"J Hypertens"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1055\/s-0029-1246185","article-title":"Mineralocorticoid antagonist treatment versus surgery in primary\n                    aldosteronism","volume":"42","author":"C Catena","year":"2010","journal-title":"Horm Metab Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1046\/j.1365-2125.1999.00070.x","article-title":"Raised aldosterone to renin ratio predicts antihypertensive efficacy of\n                    spironolactone: a prospective cohort follow-up study","volume":"48","author":"P O Lim","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/14656566.9.4.509","article-title":"Spironolactone versus eplerenone for the treatment of primary aldosteronism","volume":"9","author":"A Karagiannis","year":"2008","journal-title":"Expert Opin Parmacother"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after\n                    treatment","volume":"168","author":"C Catena","year":"2008","journal-title":"Arch Intern Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","article-title":"Long-term control of arterial hypertension and regression of left ventricular\n                    hypertrophy with treatment of primary aldosteronism","volume":"62","author":"G P Rossi","year":"2013","journal-title":"Hypertension"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/BF03349173","article-title":"Diurnal blood pressure pattern in patients with primary aldosteronism","volume":"29","author":"S Zacharieva","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1210\/jc.2008-2245","article-title":"Intrarenal hemodynamics in primary aldosteronism before and after treatment","volume":"94","author":"L A Sechi","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF03401320","article-title":"Sleep quality in patients with primary aldosteronism","volume":"13","author":"F M Hanusch","year":"2014","journal-title":"Hormones"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1245\/s10434-013-2871-3","article-title":"Medical or surgical therapy for primary aldosteronism: post-treatment follow-up\n                    as a surrogate measure of comparative outcomes","volume":"20","author":"G A Kline","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/HJH.0b013e3280108e6f","article-title":"Aldosterone as a key mediator of the cardiometabolic syndrome in primary\n                    aldosteronism: an observational study","volume":"25","author":"G Giacchetti","year":"2007","journal-title":"J Hypertens"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/EJE-12-0631","article-title":"Effectiveness of eplerenone or spironolactone treatment in preserving renal\n                    function in primary aldosteronism","volume":"168","author":"V Fourkiotis","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1210\/jc.2013-2180","article-title":"Predictors of decreasing glomerular filtration rate and prevalence of chronic\n                    kidney disease after treatment of primary aldosteronism: renal outcome of 213\n                    cases","volume":"99","author":"Y Iwakura","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1210\/jc.2011-0138","article-title":"Quality of life in patients with bilateral primary aldosteronism before and\n                    during treatment with spironolactone and\/or amiloride, including comparison with\n                    our previously published results in those with unilateral disease treated\n                    surgically","volume":"96","author":"A H Ahmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1210\/jc.2013-2805","article-title":"Long-term cardio- and cerebrovascular events in patients with primary\n                    aldosteronism","volume":"98","author":"P Mulatero","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1507\/endocrj.EJ13-0353","article-title":"Prognosis of primary aldosteronism in Japan: results from a nationwide\n                    epidemiological study","volume":"61","author":"Y Miyake","year":"2014","journal-title":"Endocr J"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/HJH.0b013e3282f4b3e6","article-title":"Primary aldosteronism: an update on screening, diagnosis and treatment","volume":"26","author":"G P Rossi","year":"2008","journal-title":"J Hypertens"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/HJH.0b013e328302ee10","article-title":"Primary aldosteronism: an update on screening, diagnosis and treatment","volume":"26","author":"N M Kaplan","year":"2008","journal-title":"J Hypertens"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(08)60834-X","article-title":"Prevalence of primary aldosteronism in resistant hypertension: a retrospective\n                    observational study","volume":"371","author":"S Douma","year":"2008","journal-title":"Lancet"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/HYPERTENSIONAHA.115.04930","article-title":"Adrenal venous sampling for differentiating unilateral from bilateral primary\n                    aldosteronism. Still the best but could be better","volume":"65","author":"M Stowasser","year":"2015","journal-title":"Hypertension"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/bmj.2.5816.729","article-title":"Comparison of surgery or prolonged spironolactone therapy in patients with\n                    hypertension, aldosterone excess, and low plasma renin","volume":"2","author":"J J Brown","year":"1972","journal-title":"Br Med J"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1161\/01.HYP.5.6_Pt_3.V115","article-title":"Studies of impaired aldosterone response to spironolactone-induced renin and\n                    potassium elevations in adenomatous but not hyperplastic primary\n                    aldosteronism","volume":"5","author":"C E Kater","year":"1983","journal-title":"Hypertension"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-131-2-199907200-00005","article-title":"Medical management of aldosterone-producing adenomas","volume":"1331","author":"R P Ghose","year":"1999","journal-title":"Ann Intern Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tem.2008.01.006","article-title":"Primary aldosteronism: cardiovascular, renal and metabolic implications","volume":"19","author":"G P Rossi","year":"2008","journal-title":"Trends Endocrinol Metab"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","article-title":"Cardiovascular complications associated with primary aldosteronism","volume":"62","author":"S Savard","year":"2013","journal-title":"Hypertension"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fendo.2014.00168","volume":"5","author":"C Catena","year":"2014","journal-title":"Front Endocrinol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: results of the PAPY Study","volume":"48","author":"G P Rossi","year":"2006","journal-title":"Hypertension"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1210\/jc.2008-1851","article-title":"Risk factors associated with a low glomerular filtration rate in primary\n                    aldosteronism","volume":"94","author":"M Reincke","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1053\/j.ajkd.2009.08.004","article-title":"The dual role of the kidney in primary aldosteronism: key determinant in rescue\n                    from volume expansion and persistence of hypertension","volume":"54","author":"L A Sechi","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1210\/jc.2005-1733","article-title":"Prevalence and characteristics of the metabolic syndrome in primary\n                    aldosteronism","volume":"91","author":"F Fallo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2161-1017.1000161","article-title":"Role of aldosterone in insulin resistance: fact or fantasy","volume":"4","author":"L A Sechi","year":"2015","journal-title":"Endocrinol Metab Synd"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism","volume":"295","author":"L A Sechi","year":"2006","journal-title":"JAMA"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"722","DOI":"10.2215\/CJN.00050107","article-title":"Relationships of plasma renin levels with renal function in patients with\n                    primary aldosteronism","volume":"2","author":"C Catena","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","article-title":"Observational study mortality in treated primary aldosteronism: the German\n                    Conn\u2019s Registry","volume":"60","author":"M Reincke","year":"2012","journal-title":"Hypertension"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/HYPERTENSIONAHA.108.114140","article-title":"Inappropriate left ventricular mass in patients with primary aldosteronism","volume":"52","author":"M L Muiesan","year":"2008","journal-title":"Hypertension"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","article-title":"Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in\n                    patients with primary aldosteronism","volume":"50","author":"C Catena","year":"2007","journal-title":"Hypertension"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","article-title":"Long-term control of arterial hypertension and regression of left ventricular\n                    hypertrophy with treatment of primary aldosteronism","volume":"62","author":"G P Rossi","year":"2013","journal-title":"Hypertension"},{"key":"ref61","first-page":"274","article-title":"Cardiovascular changes in patients with primary aldosteronism after surgical or\n                    medical treatment","volume":"35","author":"G Bernini","year":"2012","journal-title":"J Endocr Invest"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1055\/s-0032-1301902","article-title":"Predictive factors of left ventricular mass changes after treatment of primary\n                    aldosteronism","volume":"44","author":"C Catena","year":"2012","journal-title":"Horm Metab Res"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/ajh\/hpu154","article-title":"Adrenalectomy is comparable to medical treatment for reduction of left\n                    ventricular mass in primary aldosteronism: meta-analysis of long-term\n                    studies","volume":"28","author":"L Marzano","year":"2015","journal-title":"Am J Hypertens"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1530\/EJE-15-0450","article-title":"Increased prevalence of diabetes mellitus and the metabolic syndrome in patients\n                    with primary aldosteronism of the German Conn registry","volume":"173","author":"G Hanslik","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1210\/jc.2006-0736","article-title":"Insulin sensitivity in patients with primary aldosteronism: a follow-up\n                    study","volume":"91","author":"C Catena","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1210\/jc.2009-1763","article-title":"Improved quality of life, blood pressure, and biochemical status following\n                    laparoscopic adrenalectomy for unilateral primary aldosteronism","volume":"95","author":"N Sukor","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref67","first-page":"1650","article-title":"Quality of life in patients with primary aldosteronism: gender differences in\n                    untreated and long-term treated patients and associations with treatment and\n                    aldosterone","volume":"46","author":"H E Kunzel","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","article-title":"A number of marketed dihydropyridine calcium channel blockers have\n                    mineralocorticoid receptor antagonist activity","volume":"51","author":"J D Dietz","year":"2008","journal-title":"Hypertension"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective\n                    nonsteroidal molecule","volume":"285","author":"J Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"ref70","first-page":"319","article-title":"Aldosterone synthase inhibitors: pharmacological and clinical aspects","volume":"10","author":"P M Jansen","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary\n                    hypertension: results of a randomized, double-blind, placebo- and\n                    active-controlled phase 2 trial","volume":"124","author":"D A Calhoun","year":"2011","journal-title":"Circulation"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in\n                    patients with primary aldosteronism","volume":"56","author":"L Amar","year":"2010","journal-title":"Hypertension"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/HJH.0b013e32835d6d49","article-title":"Sequential comparison of aldosterone synthase inhibition and mineralocorticoid\n                    blockade in patients with primary aldosteronism","volume":"31","author":"L Amar","year":"2013","journal-title":"J Hypertens"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0035-1565128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T23:56:13Z","timestamp":1645574173000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0035-1565128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":73,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2015,12,14]]},"published-print":{"date-parts":[[2015,12]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0035-1565128","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}